IGM Biosciences is developing antibodies that are different from most monoclonal antibodies currently in use. They have two main pipeline projects focused on cancer and rheumatologic disease. The ...
Sanofi has continued the breakneck pace of dealmaking activity, paying $150 million upfront to make IGM Biosciences the third partner added in a hectic month for its business development team. The ...
Researchers discover how deficiency of IgM antibodies can lead to increased risk of arteriosclerosis
Following a blood infection, the first class of antibodies produced by the immune system are IgM antibodies. They form the "vanguard" of the immune response, before other cells are activated to fight ...
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies ...
Staphylococcus aureus, mostly known from its antibiotic-resistant variant Methicillin-resistant Staphylococcus aureus (MRSA), is among the leading causes of both community- and hospital-acquired ...
Researchers at UMC Utrecht have discovered that converting monoclonal antibodies from the IgG to the IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant ...
MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced ...
IGM Biosciences (IGMS) announced the pricing of its public offering of 8,695,653 shares of common stock at $23 per share, a 22% discount to Tuesday's closing price of $29.49. The $200 million in gross ...
IGM Biosciences is developing IgM antibodies that could have serious advantages over the antibodies used in many of today's top-selling biologic drugs. Its new collaboration deal with Sanofi could be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results